RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Sichuan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05244798, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with histologically confirmed locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM stage);

    Inclusion criterion 2

  3. New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, poorly controlled arrhythmias, or cerebrovascular accidents within 12 months before randomization.

    Exclusion criterion 4

  4. Had active tuberculosis at the time of randomization, or had received anti-tuberculosis therapy within 1 year before randomization;

    Exclusion criterion 7

    If HBsAg(+) and/or HBcAb(+) are required, HBV DNA must be < 500IU/mL. (If the lower limit of the local center's minimum detectable value is higher than 500IU/mL, after discussion with the sponsor, Enrollment was determined on a case-to-case basis) and continued to receive effective anti-HBV therapy that was already in use during the study period, or entecavir or tenofovir therapy was started prior to study medication;

    Exclusion criterion 17

  5. Physical state ECOG 0 \~ 1;

    Inclusion criterion 5

  6. Hemoglobin ≥90g/L;

    Inclusion criterion 10

    Neutrophil absolute value (ANC) ≥1.5×109/L;

    Inclusion criterion 12

    Platelet count ≥100×109/L; Total bilirubin ≤1.5× upper limit of normal (ULN);

    Inclusion criterion 13

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN;

    Inclusion criterion 14

    Prothrombin time ≤16 seconds and international normalized ratio ≤1.5×ULN; Creatinine ≤1.5×ULN or Cr clearance ≥50 mL/min (calculated using Cockcroft-Gault formula);

    Inclusion criterion 15

  7. Measurable lesions (according to RECIST v1.1);

    Inclusion criterion 7

  8. Malignant tumors other than esophageal cancer (cured localized tumors, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, were not excluded) had occurred within 5 years before randomization; Prostate cancer patients receiving hormone therapy with DFS for more than 5 years were not excluded).

    Exclusion criterion 1

    Patients with infectious diseases requiring systemic treatment (oral or intravenous administration) within 4 weeks before randomization; for active hepatitis, effective treatment was required before enrollment;

    Exclusion criterion 9

    Hcv-rna testing should be performed if HCV antibody is positive, and HCV-RNA>10\^3 copy number /mL should be excluded;

    Exclusion criterion 18

    Co-infection with HIV;

    Exclusion criterion 19

  9. Fertile women must consent to use effective contraception (e.g. intrauterine devices, birth control pills, or condoms) during the study medication period and within 60 days of the last study medication, have a negative serum pregnancy test within 7 days before study enrollment, and be non-lactating; Men agree that they must use effective contraception during the study medication period and for 60 days after the last study medication;

    Inclusion criterion 16

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05244798, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion criteria:

  • Aged 18 to 75, both sexes;
  • Patients with histologically confirmed locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM stage);
  • Cervical contrast-enhanced CT showed no suspicious metastatic lymph nodes. Imaging examination showed no systemic metastasis.
  • R0 resection is expected to be achieved;
  • Physical state ECOG 0 \~ 1;
  • No previous antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including radiotherapy planned during the study), hormone therapy, and immunotherapy;
  • Measurable lesions (according to RECIST v1.1);
  • There was no operation contraindications in the evaluation of various organ functions before operation;
  • The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for study participation:
  • Hemoglobin ≥90g/L;
  • White blood cell count ≥ lower limit of laboratory normal;
  • Neutrophil absolute value (ANC) ≥1.5×109/L;
  • Platelet count ≥100×109/L; Total bilirubin ≤1.5× upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN;
  • Prothrombin time ≤16 seconds and international normalized ratio ≤1.5×ULN; Creatinine ≤1.5×ULN or Cr clearance ≥50 mL/min (calculated using Cockcroft-Gault formula);
  • Fertile women must consent to use effective contraception (e.g. intrauterine devices, birth control pills, or condoms) during the study medication period and within 60 days of the last study medication, have a negative serum pregnancy test within 7 days before study enrollment, and be non-lactating; Men agree that they must use effective contraception during the study medication period and for 60 days after the last study medication;
  • The informed consent must be understood and signed.

Exclusion criteria:

Patients who met any of the following criteria were excluded from the study:

  • Malignant tumors other than esophageal cancer (cured localized tumors, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, were not excluded) had occurred within 5 years before randomization; Prostate cancer patients receiving hormone therapy with DFS for more than 5 years were not excluded).
  • Patients with high blood tendency who had a history of gastrointestinal bleeding within 6 months before randomization, or had coagulopathy at the time of enrollment, or were receiving thrombolysis or anticoagulant therapy;
  • Severe cardiovascular and cerebrovascular diseases:
  • New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, poorly controlled arrhythmias, or cerebrovascular accidents within 12 months before randomization.

LVEF (left ventricular ejection fraction) <50% on echocardiography. Corrected QT interval (QTc) >480ms (calculated using Fridericia's method; if QTc was abnormal, three consecutive tests were performed at 2 min intervals and the mean value was taken).

Medically difficult to control hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100mmHg) (based on the average of ≥2 measurements).

  • A previous hypertensive crisis or hypertensive encephalopathy.
  • Previous history of interstitial lung disease or pneumonia requiring steroid treatment at enrollment;
  • Had active tuberculosis at the time of randomization, or had received anti-tuberculosis therapy within 1 year before randomization;
  • Asthma at random requiring intermittent use of bronchodilators or other medical interventions;
  • Patients with infectious diseases requiring systemic treatment (oral or intravenous administration) within 4 weeks before randomization; for active hepatitis, effective treatment was required before enrollment;
  • Severe unhealed wounds, active ulcers, and untreated fractures at random;
  • Combined with other inoperable conditions;
  • The previous operation resulted in the inability to use stomach instead of esophagus to reconstruct the digestive tract in this operation;
  • Was receiving systemic steroid therapy (more than 10mg of prednisone daily or equivalent) or other immunosuppressive agents during the 2 weeks prior to randomization;
  • Severe allergy to chemotherapy drugs (albumin paclitaxel or cisplatin) or any monoclonal antibody;
  • Has had an active autoimmune disease requiring systemic treatment (i.e., immunomodulatory drugs, corticosteroids, or immunomodulatory drugs) in the past 2 years; However, replacement therapy (e.g., thyroxine, insulin, or replacement therapy with physiologic corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy and is allowed for use and enrollment;
  • Previous organ transplant recipients;
  • If HBsAg(+) and/or HBcAb(+) are required, HBV DNA must be < 500IU/mL. (If the lower limit of the local center's minimum detectable value is higher than 500IU/mL, after discussion with the sponsor, Enrollment was determined on a case-to-case basis) and continued to receive effective anti-HBV therapy that was already in use during the study period, or entecavir or tenofovir therapy was started prior to study medication;
  • Hcv-rna testing should be performed if HCV antibody is positive, and HCV-RNA>10\^3 copy number /mL should be excluded;
  • Co-infection with HIV;
  • In the judgment of the investigator, there are other circumstances that are not suitable for participating in the study.

Quoted from ClinicalTrials.gov, NCT05244798, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05244798, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05244798